NVP-ACC789

Research use only, not for human use.

ACC-789 (NVP-ACC789; ZK-202650) is an effective, specific and orally active inhibitor of the VEGF receptor tyrosine kinases.

ACC-789, also known as NVP-ACC789 and ZK-202650, is a potent, selective and orally active inhibitor of the VEGF receptor tyrosine kinases with potential anticancer activity.

The enzymatic kinase assays demonstrate that NVP-ACC789 is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. In VEGF-treated cultures, addition of the VEGFR-2 inhibitor NVP-ACC789 reduces BME cell number to baseline levels from 1 μM. Likewise, bFGF-induced BME cell proliferation is reduced markedly by NVP-ACC789 from 1 to 10 μM, without however reaching basal levels. NVP-ACC789 is found to be a potent inhibitor of VEGF-induced HUVE cell proliferation with an IC50 of 1.6 nM. NVP-ACC789 also completely inhibits VEGF-induced BME and BAE cell invasion and VEGF-C-induced BAE cell invasion. The inhibition is dose-dependent in both cell types with a maximal effect from 1 μM.

NVP-ACC789 which is given in daily oral doses for 6 days blocks VEGF-induced angiogenesis in a dose-dependent manner. NVP-ACC789 also inhibits the response to bFGF to some extent, but the dose-response curve is not linear for NVP-ACC789.

NVP-ACC789 | NVP-ACC 789 | NVP-ACC-789 | ACC-789

Others

Other Targets

VEGFR

——

——

300842-64-2

405.3

C21H17BrN4

>98% (HPLC)

DMSO : 60 mg/mL 148.04 mM;

c1(nnc(c2ccccc12)Cc1ccncc1)Nc1cc(c(cc1)C)Br

N-(3-Bromo-4-methylphenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine

(-20℃)

With Ice Pack

≥ 2 years